home / stock / crdl / crdl quote
Last: | $2.165 |
---|---|
Change Percent: | -10.17% |
Open: | $2.5 |
Close: | $2.41 |
High: | $2.52 |
Low: | $2.16 |
Volume: | 1,018,644 |
Last Trade Date Time: | 06/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.165 | $2.5 | $2.41 | $2.52 | $2.16 | 1,018,644 | 06-17-2024 |
$2.41 | $2.56 | $2.41 | $2.59 | $2.39 | 672,714 | 06-14-2024 |
$2.36 | $2.99 | $2.36 | $3 | $2.31 | 2,998,502 | 06-13-2024 |
$2.97 | $3 | $2.97 | $3.12 | $2.84 | 1,505,554 | 06-12-2024 |
$2.86 | $2.9 | $2.86 | $2.98 | $2.72 | 773,938 | 06-11-2024 |
$2.86 | $2.51 | $2.86 | $2.895 | $2.5091 | 1,849,595 | 06-10-2024 |
$2.41 | $2.53 | $2.41 | $2.53 | $2.3202 | 410,348 | 06-07-2024 |
$2.49 | $2.53 | $2.49 | $2.54 | $2.4 | 588,967 | 06-06-2024 |
$2.55 | $2.69 | $2.55 | $2.73 | $2.46 | 640,197 | 06-05-2024 |
$2.62 | $2.81 | $2.62 | $2.81 | $2.55 | 629,602 | 06-04-2024 |
$2.78 | $2.64 | $2.78 | $2.79 | $2.64 | 698,846 | 06-03-2024 |
$2.62 | $2.66 | $2.62 | $2.66 | $2.52 | 472,025 | 05-31-2024 |
$2.57 | $2.42 | $2.57 | $2.65 | $2.4101 | 761,210 | 05-30-2024 |
$2.4 | $2.34 | $2.4 | $2.42 | $2.34 | 333,164 | 05-29-2024 |
$2.345 | $2.4 | $2.345 | $2.44 | $2.28 | 200,395 | 05-28-2024 |
$2.35 | $2.27 | $2.35 | $2.4 | $2.25 | 730,320 | 05-27-2024 |
$2.35 | $2.27 | $2.35 | $2.4 | $2.25 | 730,320 | 05-24-2024 |
$2.23 | $2.29 | $2.23 | $2.34 | $2.18 | 265,851 | 05-23-2024 |
$2.18 | $2.2 | $2.18 | $2.33 | $2.16 | 275,822 | 05-22-2024 |
$2.22 | $2.18 | $2.22 | $2.29 | $2.1508 | 191,065 | 05-21-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cardiol Therapeutics Inc. Company Name:
CRDL Stock Symbol:
NASDAQ Market:
(NewsDirect) In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II MAvERIC-Pilot study topline results. The Canadian biotechnology compan...
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis pain CardiolRx™ also shown to reduce inflammation in patients with elevated CRP 89% of patients have continued into the extension phase of the study Toronto, Ontario--(Newsfile...
(NewsDirect) Compared to their non-orphan counterparts, orphan drugs have consistently outpaced growth and have become a major part of pharma’s mainstream business. The U.S. FDA's orphan drug designation, established under the Orphan Drug Act of 1983, encourages the development of trea...